Forte Biosciences, Inc.
- Market Cap (Float-Adj) (Float-adjusted market cap computed by the low-float screener — matches the screener row. May differ from the standard cap (price × all shares outstanding) reported elsewhere.)
- $421.5M
- Price
- $20.58
- % Change (Daily % change from the live per-ticker quote feed.)
- -7.51%
- Volume
- 590.1K
Quote data as of 5:26 AM ET
About
Forte Biosciences, Inc. is a U.S.-based biopharmaceutical company currently in its clinical development phase. The firm's key initiative involves advancing the FB-102 program, which is designed to tackle a variety of autoimmune conditions, notably vitiligo and alopecia areata. Their main offices are situated in Dallas, Texas.
Quick stats
Shares outstanding20.5M
Computed float7.5M
Float sourceUnknown
Cash runway (months)7.3
Dilution risk—
Has warrants—
Has convertibles—
Active shelf (Shelf registration (e.g. Form S-3) currently in effect — the company is pre-cleared to issue and sell new shares quickly. A standing dilution risk.)—
Active ATM (At-the-market offering — a program to sell newly issued shares directly into the open market at prevailing prices, diluting existing holders over time.)—
Key info
SectorHealthcare
IndustryBiotechnology
CIK (Central Index Key — the unique ID the SEC assigns to every filer. Use it to look up the company's filings on EDGAR.)0001419041
Websitehttps://www.fortebiorx.com
AI Summary
AI-generated2mo agominorneutralexecutive changeForte Biosciences, Inc. Reports Inducement Grant Under Nasdaq Listing Rules
Forte Biosciences granted equity awards to a new non-executive employee, including options to purchase 50,000 shares and restricted stock units representing 50,000 shares.
The options vest over four years, with 25% vesting on the one-year anniversary of employment and the remaining 75% vesting monthly over the next 36 months.
The restricted stock units also vest over four years, with 25% vesting annually on the anniversary of the grantee’s employment commencement date.